Alloy Therapeutics

Alloy Therapeutics

Growth Stage

Better medicine, together

Better medicine, together


Funding data not publicly available


Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegD 506(c)

Pre-Money Valuation


Year Founded



Business Services, Software, & Applications

Tech Sector



Waltham, Massachusetts

Alloy Therapeutics, with a valuation of $450 million, is raising funds on OurCrowd through Reg D 506(c) raise. The company has developed a platform that enables collaboration among scientists and democratizes access to foundational drug discovery platforms. The aim of the business is to make drug discovery and creation easier and more efficient. Alloy Therapeutics empowers drug discovery across six biologic modalities, including antibodies, TCRS, genetic medicines, peptides, cell therapies, and delivery. Errik Anderson founded Alloy Therapeutics in 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,120,000. The campaign proceeds will be used for growth and expansion.
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Alloy Therapeutics on OurCrowd 2021
Platform: OurCrowd
Security Type: Equity - Common
Valuation: $450,000,000

Follow company

Follow Alloy Therapeutics on OurCrowd 2021

Buy Alloy Therapeutics's Deal Report

Warning: according to the close date for this deal, Alloy Therapeutics may no longer be accepting investments.

Alloy Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Alloy Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Alloy Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Alloy Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge